- Home
- DNMX vs OBIO Comparison
DNMX vs OBIO Comparison
Compare DNMX & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DNMX | OBIO |
|---|---|---|
| Founded | 2025 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 269.9M | 253.9M |
| IPO Year | 2025 | 2020 |
Fundamental Metrics
Financial Performance| Metric | DNMX | OBIO |
|---|---|---|
| Price | $10.06 | $6.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $14.25 |
| AVG Volume (30 Days) | 63.4K | ★ 313.0K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $33,482,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.43 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 1169.22 |
| 52 Week Low | $9.87 | $2.40 |
| 52 Week High | $10.08 | $6.48 |
Technical Indicators
Market Signals| Indicator | DNMX | OBIO |
|---|---|---|
| Relative Strength Index (RSI) | 49.66 | 60.37 |
| Support Level | $9.99 | $3.83 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.01 | 0.41 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 25.00 | 69.35 |
Price Performance
Historical ComparisonAbout DNMX Dynamix Corporation III Class A Ordinary Shares
Dynamix Corp III is a blank check company.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.